Gore has announced that it has received approval to apply the CE mark and commence commercial distribution of the Viabahn endoprosthesis with propaten bioactive surface in the European Union. The device combines Gore’s proprietary heparin surface with the Viabahn endoprosthesis for treatment of arterial vascular disease. It is indicated for the endovascular grafting of peripheral arteries.
The Viabahn with propaten uses endpoint covalent bonding to keep the heparin anchored to the endoprosthesis surface over time. The proprietary endpoint surface attachment technology preserves the heparin bioactive sites such that they remain free to interact with the blood without being consumed.
The product (5mm to 8mm devices) is available with a low-profile delivery system that gives interventionalists a more streamlined approach to re-line the peripheral arteries. The Viabahn Endoprosthesis is constructed with a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure. The flexibility enables it to better traverse tortuous areas of the SFA and conform more closely to the complex anatomy of the artery.